Journal
CELL CYCLE
Volume 14, Issue 4, Pages 481-487Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2015.1006048
Keywords
epithelial-mesenchymal transition; drug resistance; metastasis; radioresistance; ZEB1
Categories
Funding
- US National Institutes of Health [R01CA166051, R01CA181029]
- Cancer Prevention and Research Institute of Texas Scholar Award [R1004]
- Jeanne F. Shelby Scholarship Fund
Ask authors/readers for more resources
Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor that promotes tumor invasion and metastasis by inducing epithelial-mesenchymal transition (EMT) in carcinoma cells. EMT not only plays an important role in embryonic development and malignant progression, but is also implicated in cancer therapy resistance. It has been hypothesized that carcinoma cells that have undergone EMT acquire cancer stem cell properties including self-renewal, chemoresistance and radioresistance. However, our recent data indicate that ZEB1 regulates radioresistance in breast cancer cells through an EMT-independent mechanism. In this Perspective, we review different mechanisms by which ZEB1 regulates tumor progression and treatment resistance. Based on studies by us and others, we propose that it is specific EMT inducers like ZEB1, but not the epithelial or mesenchymal state itself, that dictate cancer stem cell properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available